NNVC - NanoViricides, Inc. - News:NanoViricides, Inc. to Tackle Asian Bird Flu
10/3/2005 1:19:01 PM
WEST HAVEN, Conn., Oct 03, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced that it is moving rapidly forward with its strategy for combating Avian Flu. "If our FluCide-I influenza drug meets the initial expectations, we can modify it very quickly to develop a nanoviricide against the avian flu," explained Dr. Diwan, President, "We simply reset the nanoviricide's target to H5N1, the bird flu virus!" The Company has scheduled high-level meetings in December with Vietnam's senior government officials and scientists regarding avian flu. "This invitation by the Vietnamese government gives us an enormous advantage over most other companies, including large cap biotech firms," said the CEO, Eugene Seymour, MD, MPH. The Company anticipates having preclinical data available to share on its Flucide-I influenza (nanoviricide) drug and considers this a unique opportunity to access the wealth of information available in Vietnam on bird flu.
Two days ago, the US Senate passed a $4 Billion bill to purchase TamiFlu(TM) (Roche) and also to pursue additional strategies for prevention as well as treatment. Tamiflu(TM) has limited effectiveness but remains the only means of treatment against avian flu at present. The Senate funding move came the same day the United Nations' new avian flu coordinator Dr. David Nabarro warned that a flu pandemic could kill millions of people worldwide.
"Developing targeted therapies for both usual Influenza and Avian Flu will enable the company to tap into the billions of dollars now available from both the Department of Defense and the Department of Homeland Security," Dr. Seymour continued, "We are now giving the highest priority to Influenza and Avian Flu."
https://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile.
SOURCE: NanoViricides, Inc.
NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
.